0.975
-0.07 (-6.25%)
AIStockmoo 评分
| 价值 30% | -2.1 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 资本回报低于资本成本。资本回报下降。 参考 | |
| 时机 30% | -4.1 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| K线形态 参考 | NA |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | -1.4 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净-0.52%的股份:23家增持,18家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+39.2%,回补天数5.5天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 股价接近支撑位。支撑与阻力水平趋降。 参考 | |
| 最终评分 | -2.99 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Gain Therapeutics, Inc. | 混合的 | 混合的 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| GANX | - | - | - | 4.54 |
| TRML | 1 B | - | - | 4.76 |
| TECH | - | 0.44% | - | 5.28 |
| MLTX | - | - | - | 2.79 |
| VKTX | - | - | - | 6.33 |
| VSTM | - | - | - | 76.50 |
|
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.78% |
| 机构持股比例 | 8.14% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 30 Sep 2026 | 566,645 |
| Dme Capital Management, Lp | 30 Jun 2026 | 566,130 |
| Cresset Asset Management, Llc | 30 Jun 2026 | 160,000 |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 20.51%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 23 | 865,600 |
| 减持 | 18 | 1,105,450 |
| 新建仓 | 11 | 427,858 |
| 清仓 | 6 | 422,295 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 3,891,227 | 5.5 |
| 15 Oct 2026 | 3,191,453 | 6.5 |
| 30 Sep 2026 | 3,056,188 | 5.9 |
| 15 Sep 2026 | 2,887,151 | 8.9 |
| 31 Aug 2026 | 2,795,819 | 7.7 |
| 14 Aug 2026 | 2,952,391 | 4.9 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
| 10 Nov 2026 | Yahoo Finance |
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the… |
| 05 Nov 2026 | Yahoo Finance |
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two… |
| 08 Oct 2026 | Yahoo Finance |
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the… |
| 01 Oct 2026 | Yahoo Finance |
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants with both high and low baseline levels of GluSph… |
| 29 Sep 2026 | Yahoo Finance |
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at… |
| 17 Sep 2026 | Yahoo Finance |
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President… |
| 25 Aug 2026 | Yahoo Finance |
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President… |
投资组合